See more : Veken Technology Co., Ltd. (600152.SS) Income Statement Analysis – Financial Results
Complete financial analysis of EDAP TMS S.A. (EDAP) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EDAP TMS S.A., a leading company in the Medical – Devices industry within the Healthcare sector.
- Maire Tecnimont S.p.A. (3OY1.F) Income Statement Analysis – Financial Results
- Karnov Group AB (publ) (KAR.ST) Income Statement Analysis – Financial Results
- Wallenius Wilhelmsen ASA (WAWIO.XD) Income Statement Analysis – Financial Results
- Sixty North Gold Mining Ltd. (SXTY.CN) Income Statement Analysis – Financial Results
- Coastal Caribbean Oils & Minerals, Ltd. (COCBF) Income Statement Analysis – Financial Results
EDAP TMS S.A. (EDAP)
About EDAP TMS S.A.
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.42M | 55.11M | 44.07M | 41.66M | 44.91M | 39.18M | 35.75M | 35.61M | 32.25M | 26.79M | 24.08M | 26.07M | 22.29M | 23.71M | 24.89M | 23.05M | 22.36M | 20.27M | 20.79M | 22.15M | 18.44M | 19.98M | 24.01M | 27.33M | 19.16M | 23.19M | 32.73M |
| Cost of Revenue | 36.01M | 30.92M | 25.64M | 23.28M | 23.91M | 22.27M | 20.94M | 19.20M | 18.47M | 15.58M | 14.76M | 15.63M | 13.44M | 14.25M | 14.21M | 13.96M | 13.17M | 11.95M | 12.30M | 13.67M | 13.07M | 11.51M | 15.22M | 14.23M | 10.77M | 11.60M | 16.18M |
| Gross Profit | 24.41M | 24.19M | 18.42M | 18.38M | 21.00M | 16.92M | 14.81M | 16.41M | 13.79M | 11.20M | 9.32M | 10.43M | 8.86M | 9.46M | 10.67M | 9.10M | 9.19M | 8.32M | 8.49M | 8.48M | 5.37M | 8.47M | 8.79M | 13.10M | 8.39M | 11.60M | 16.55M |
| Gross Profit Ratio | 40.40% | 43.90% | 41.81% | 44.11% | 46.76% | 43.17% | 41.43% | 46.08% | 42.74% | 41.82% | 38.70% | 40.03% | 39.73% | 39.88% | 42.89% | 39.47% | 41.11% | 41.05% | 40.83% | 38.29% | 29.12% | 42.37% | 36.62% | 47.92% | 43.77% | 50.00% | 50.56% |
| Research & Development | 6.96M | 4.92M | 3.40M | 4.50M | 3.73M | 4.09M | 3.88M | 3.87M | 2.69M | 2.93M | 2.60M | 2.66M | 2.44M | 3.27M | 3.65M | 4.26M | 3.20M | 2.44M | 1.78M | 1.52M | 3.06M | 3.19M | 3.44M | 3.98M | 3.14M | 3.24M | 3.36M |
| General & Administrative | 14.63M | 7.15M | 5.90M | 4.34M | 4.22M | 3.59M | 3.43M | 3.30M | 3.20M | 3.33M | 3.20M | 3.19M | 3.04M | 3.32M | 3.82M | 3.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 22.63M | 16.38M | 10.73M | 9.28M | 10.85M | 10.55M | 9.53M | 8.86M | 7.41M | 6.68M | 6.28M | 6.62M | 5.87M | 6.68M | 6.40M | 5.68M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 37.26M | 23.53M | 16.63M | 13.61M | 15.07M | 14.14M | 12.95M | 12.15M | 10.61M | 10.01M | 9.48M | 9.81M | 8.92M | 10.01M | 10.22M | 9.55M | 9.87M | 8.70M | 8.03M | 7.47M | 10.44M | 9.92M | 9.59M | 11.51M | 11.57M | 12.96M | 12.55M |
| Other Expenses | 1.00K | 0.00 | 0.00 | -1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 174.57K | 0.00 | 0.00 | -282.00K | 0.00 | 0.00 | 0.00 | 0.00 | 224.28K | 267.46K | 0.00 | 317.20K | -23.03K | 136.27K | 92.16K | 1.35M | 1.80M | 1.53M | 1.45M |
| Operating Expenses | 44.22M | 28.45M | 20.04M | 18.11M | 18.80M | 18.23M | 16.84M | 16.02M | 13.30M | 12.94M | 12.07M | 12.46M | 11.35M | 13.27M | 13.87M | 13.80M | 13.29M | 11.41M | 9.81M | 9.31M | 13.48M | 13.25M | 13.12M | 16.84M | 16.51M | 17.74M | 17.36M |
| Cost & Expenses | 80.24M | 59.37M | 45.68M | 41.39M | 42.71M | 40.50M | 37.77M | 35.22M | 31.77M | 28.52M | 26.84M | 28.10M | 24.79M | 27.53M | 28.09M | 27.76M | 26.46M | 23.36M | 22.12M | 22.98M | 26.55M | 24.76M | 28.33M | 31.07M | 27.28M | 29.33M | 33.55M |
| Interest Income | 1.31M | 404.00K | 10.00K | 10.00K | 20.00K | 19.00K | 18.00K | 21.00K | 18.00K | 31.00K | 59.00K | 126.00K | 185.00K | 265.00K | 252.00K | 412.00K | 331.28K | 224.28K | 186.59K | 146.06K | 177.07K | 455.52K | 992.41K | 0.00 | 0.00 | 511.60K | 0.00 |
| Interest Expense | 232.00K | 168.00K | 52.00K | 108.00K | 165.00K | 111.00K | 44.00K | 57.00K | 64.00K | 65.00K | 1.97M | 2.07M | 875.00K | 2.14M | 1.45M | 1.41M | 378.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.91M | 1.61M | 2.00M | 2.06M | 2.07M | 1.52M | 1.48M | 1.07M | 1.00M | 900.00K | 1.18M | 931.00K | 1.41M | 1.23M | 1.80M | 1.79M | 1.30M | 1.26M | 1.20M | 1.05M | 981.42K | 1.12M | 1.10M | 1.35M | 1.80M | 1.53M | 1.45M |
| EBITDA | -18.39M | -323.00K | 309.00K | 2.37M | 2.06M | 295.00K | 1.32M | 1.38M | 1.45M | 569.00K | -1.74M | -1.15M | -2.93M | -8.41M | -4.44M | 4.85M | -3.90M | -1.13M | -119.89K | 614.49K | -7.13M | -3.66M | -3.22M | -2.40M | -6.32M | -4.60M | 636.36K |
| EBITDA Ratio | -30.43% | -11.22% | -9.02% | 3.91% | 4.60% | -4.73% | -3.13% | 0.81% | -0.66% | -4.88% | -6.33% | -13.57% | -13.14% | -19.83% | -4.63% | -10.95% | -5.43% | -5.60% | -1.67% | 2.77% | -34.83% | -21.76% | -62.67% | -77.40% | -42.65% | -14.71% | -1.11% |
| Operating Income | -19.81M | -4.26M | -1.61M | -477.00K | 185.00K | -1.32M | -2.03M | 392.00K | 488.00K | -1.74M | -2.76M | -2.03M | -2.50M | 3.82M | 3.20M | 4.70M | 4.10M | 3.09M | 1.32M | 829.15K | 8.11M | 4.78M | 5.12M | 3.75M | -8.12M | 6.14M | -818.18K |
| Operating Income Ratio | -32.79% | -7.72% | -3.66% | -1.14% | 0.41% | -3.36% | -5.67% | 1.10% | 1.51% | -6.48% | -11.44% | -7.79% | -11.20% | 16.10% | 12.87% | 20.40% | 18.31% | 15.27% | 6.36% | 3.74% | 43.96% | 23.93% | 21.34% | 13.71% | -42.36% | 26.47% | -2.50% |
| Total Other Income/Expenses | -720.00K | 2.16M | 2.51M | -711.00K | 2.01M | 1.34M | 1.73M | 4.05M | -1.40M | 1.34M | -2.13M | -5.33M | 1.95M | -7.96M | -10.90M | -3.06M | -9.67M | -6.47M | -2.28M | -1.70M | -17.18M | -8.66M | 2.91M | 8.32M | 1.61M | -13.22M | 909.09K |
| Income Before Tax | -20.53M | -2.10M | 893.00K | -1.19M | 2.19M | 20.00K | -294.00K | 4.44M | -907.00K | -396.00K | -4.89M | -7.36M | -543.00K | -11.78M | -7.69M | 1.11M | -5.58M | -3.37M | -959.98K | -870.46K | -9.07M | -3.88M | 8.03M | 12.07M | -6.51M | -7.08M | 90.91K |
| Income Before Tax Ratio | -33.98% | -3.80% | 2.03% | -2.85% | 4.88% | 0.05% | -0.82% | 12.48% | -2.81% | -1.48% | -20.29% | -28.23% | -2.44% | -49.68% | -30.92% | 4.79% | -24.95% | -16.65% | -4.62% | -3.93% | -49.21% | -19.40% | 33.46% | 44.15% | -33.95% | -30.51% | 0.28% |
| Income Tax Expense | 644.00K | 837.00K | 193.00K | 516.00K | 679.00K | 358.00K | 388.00K | 602.00K | 759.00K | 116.00K | 135.00K | 118.00K | 395.00K | 939.00K | 72.00K | -492.00K | -139.92K | 56.07K | 103.85K | 278.11K | -113.55K | 166.77K | 883.39K | 323.68K | -256.40K | 85.27K | -90.91K |
| Net Income | -21.18M | -2.93M | 700.00K | -1.70M | 1.51M | -338.00K | -681.00K | 3.84M | -1.67M | -512.00K | -5.02M | -7.48M | -938.00K | -12.72M | -7.77M | 1.60M | -5.44M | -3.43M | -1.06M | -1.15M | -8.96M | -4.04M | 7.15M | 11.74M | -6.25M | -7.16M | 181.82K |
| Net Income Ratio | -35.05% | -5.32% | 1.59% | -4.09% | 3.37% | -0.86% | -1.91% | 10.79% | -5.17% | -1.91% | -20.85% | -28.68% | -4.21% | -53.64% | -31.21% | 6.93% | -24.32% | -16.93% | -5.12% | -5.18% | -48.59% | -20.24% | 29.78% | 42.97% | -32.61% | -30.88% | 0.56% |
| EPS | -0.57 | -0.09 | 0.02 | -0.06 | 0.05 | -0.01 | -0.02 | 0.14 | -0.07 | -0.02 | -0.24 | -0.43 | -0.07 | -0.98 | -0.74 | 0.17 | -0.59 | -0.39 | -0.14 | -0.15 | -1.15 | -0.52 | 0.92 | 1.50 | -0.80 | -0.86 | 0.03 |
| EPS Diluted | -0.57 | -0.09 | 0.02 | -0.06 | 0.05 | -0.01 | -0.02 | 0.13 | -0.07 | -0.02 | -0.24 | -0.43 | -0.07 | -0.97 | -0.73 | 0.17 | -0.59 | -0.36 | -0.13 | -0.14 | -1.15 | -0.52 | 0.90 | 1.42 | -0.80 | -0.86 | 0.03 |
| Weighted Avg Shares Out | 37.00M | 34.39M | 32.13M | 29.15M | 29.02M | 29.00M | 28.96M | 27.82M | 23.81M | 23.60M | 20.59M | 17.38M | 13.35M | 13.01M | 10.51M | 9.58M | 9.20M | 8.82M | 7.78M | 7.78M | 7.78M | 7.77M | 7.76M | 7.78M | 7.80M | 8.32M | 6.67M |
| Weighted Avg Shares Out (Dil) | 37.00M | 34.39M | 32.42M | 29.15M | 29.62M | 29.00M | 28.96M | 29.37M | 25.02M | 23.60M | 20.59M | 17.56M | 13.35M | 13.09M | 10.57M | 9.66M | 9.20M | 9.56M | 8.37M | 8.07M | 7.82M | 7.83M | 7.94M | 8.27M | 7.80M | 8.32M | 6.67M |
Landmark HIFI Study Publication Demonstrates Positive Outcomes with Focal One® Robotic HIFU Versus Surgery in the Management of Prostate Cancer
EDAP Announces Scientific Presentation at 2024 AAGL Global Congress Comparing Focal One HIFU Versus Surgery for the Treatment of Deep Infiltrating Endometriosis
EDAP TMS S.A. (EDAP) Q3 2024 Earnings Call Transcript
EDAP to Announce Third Quarter 2024 Financial Results on November 7, 2024
EDAP's Avenda Deal for AI-Assisted Cancer Care Likely to Drive Stock
EDAP and Avenda Health Launch World's First AI-Assisted Focal One® Robotic HIFU Procedures
EDAP to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
EDAP TMS S.A. (EDAP) Q2 2024 Earnings Call Transcript
EDAP Reports Second Quarter 2024 Financial Results
EDAP to Announce Second Quarter 2024 Financial Results on August 28, 2024
Source: https://incomestatements.info
Category: Stock Reports